Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mylan/Biocon’s Insulin Glargine Has Narrow Window For Approval In US

Executive Summary

Thirty-month stay resulting from Sanofi’s patent lawsuit expires on 18 March 2020, two days before Mylan’s application must receive final approval to avoid getting caught in the transition of insulins from drug to biologic regulation. Pre-approval inspection of Biocon’s manufacturing facility resulted in 12 ‘largely procedural’ observations, company says.


Related Content

House Appropriators Tip-Toe Into Biologics Transition Controversy
Biologics Transition 'Dead Zone' Could Be Eliminated Under US Senate Bill
A Guide To US FDA’s Drug-To-Biologic Transition Process
Insulin Maker Lilly Seeks US FDA Assurances On ‘Authorized Biologics’
Mylan Scores IPR Victory, Paving The Way For Follow-On Lantus
Keeping Track: Mylan Wins First US FDA Approval For Neulasta Biosimilar, But Lands A CRL For Insulin Glargine; Genentech Nabs Broad Full Approval For Venclexta, PV Indication For Rituxan
GMP Lapses At Biocon’s Indian Site – Jitters for Neulasta Biosimilar Plans?
Sanofi Settlement With Lilly Paves The Way For Biosimilar Lantus


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts